Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.
about
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody.Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.
P2860
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Proteolytic cleavage of antige ...... nti-PCSK9 monoclonal antibody.
@en
type
label
Proteolytic cleavage of antige ...... nti-PCSK9 monoclonal antibody.
@en
prefLabel
Proteolytic cleavage of antige ...... nti-PCSK9 monoclonal antibody.
@en
P2093
P2860
P356
P1476
Proteolytic cleavage of antige ...... nti-PCSK9 monoclonal antibody.
@en
P2093
Krista M Schroeder
Mark C Kowala
Patrick I Eacho
Richard T Pickard
Ryan J Hansen
Thomas P Beyer
Victor J Wroblewski
P2860
P304
P356
10.1194/JLR.M061903
P577
2015-09-20T00:00:00Z